EI

281.3

+0.32%↑

SAN

86.85

+1.88%↑

MRK1

120.85

+3.16%↑

SHL.DE

47.49

+1.04%↑

UCB

252.2

+2.69%↑

EI

281.3

+0.32%↑

SAN

86.85

+1.88%↑

MRK1

120.85

+3.16%↑

SHL.DE

47.49

+1.04%↑

UCB

252.2

+2.69%↑

EI

281.3

+0.32%↑

SAN

86.85

+1.88%↑

MRK1

120.85

+3.16%↑

SHL.DE

47.49

+1.04%↑

UCB

252.2

+2.69%↑

EI

281.3

+0.32%↑

SAN

86.85

+1.88%↑

MRK1

120.85

+3.16%↑

SHL.DE

47.49

+1.04%↑

UCB

252.2

+2.69%↑

EI

281.3

+0.32%↑

SAN

86.85

+1.88%↑

MRK1

120.85

+3.16%↑

SHL.DE

47.49

+1.04%↑

UCB

252.2

+2.69%↑

Search

Orion Oyj (Class B)

Uždarymo kaina

64.95 -0.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

64.6

Max

65.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

119M

180M

Pardavimai

62M

417M

P/E

Sektoriaus vid.

23.959

35.739

Pelnas, tenkantis vienai akcijai

0.59

Dividendų pajamingumas

2.57

Pelno marža

43.289

Darbuotojai

3,700

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.57%

3.08%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

192M

9.1B

Ankstesnė atidarymo kaina

65.1

Ankstesnė uždarymo kaina

64.95

Orion Oyj (Class B) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-02 23:30; UTC

Karštos akcijos

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025-10-02 21:21; UTC

Uždarbis

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025-10-03 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025-10-02 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025-10-02 23:39; UTC

Rinkos pokalbiai

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025-10-02 23:00; UTC

Rinkos pokalbiai

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Scales's JV Buyout Lauded by Bull -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-02 21:17; UTC

Įsigijimai, susijungimai, perėmimai

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025-10-02 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-02 20:49; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025-10-02 20:00; UTC

Įsigijimai, susijungimai, perėmimai

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025-10-02 19:20; UTC

Rinkos pokalbiai

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025-10-02 19:10; UTC

Rinkos pokalbiai

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025-10-02 19:04; UTC

Rinkos pokalbiai

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025-10-02 18:43; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Akcijų palyginimas

Kainos pokytis

Orion Oyj (Class B) Prognozė

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
help-icon Live chat